Just now, the Jiangxi Provincial Medical Insurance Bureau announced that the National Symposium on Centralized Pharmaceutical Procurement and Price Management was held in Shijiazhuang City, Hebei Province.
The meeting comprehensively summarized the price bidding and procurement work in 2022, analyzed the current situation and tasks, and deployed the centralized pharmaceutical procurement and price management work in 2023. Shi Zihai, a member of the Party Leadership Group and Deputy Director General of the National Health Insurance Bureau, attended the meeting, and the leaders of the medical insurance bureaus of various provinces, autonomous regions, and municipalities directly under the Central Government in charge of pharmaceutical pricing and bidding procurement departments participated in the meeting. He Sang, a member of the Party Leadership Group and Deputy Director General of Jiangxi Medical Insurance Bureau, exchanged experiences on four tasks, including the centralized collection of liver function biochemical reagents.
The provincial alliance for liver function biochemical testing reagents in 23 provinces collected products, with an average decrease of 68.64%. Among them, low density lipoprotein (LDL) decreased by as much as 95.64%. The alliance province can save 2 billion yuan, achieving a win-win situation of enterprise volume and mass burden reduction. We will simultaneously carry out special price adjustments for reagent testing and medical services, and consolidate the results of centralized purchase and price reduction of liver function biochemical testing reagents.
From Guangdong leading the COVID-19 Reagent Carrying Alliance in 2021 to Jiangxi leading the Hepatic Biochemical Reagent Carrying Alliance in 2022, to Anhui leading the Alliance in 2023. In the future, it is likely that other provinces will take the lead in the centralized procurement of other categories of testing reagents with a volume alliance.
"It's just a gradual process that gives the industry a buffer time, but I don't think this is to say that IVD is different from drugs and there will be special treatment.".
At present, in the tide of domestic substitution, innovation, technology, and quality are important factors in breaking the import monopoly. The centralized purchase of conventional products with a large quantity also explains the development direction of the future industry. Many small and medium-sized enterprises are involved in OEM and sub packaging. In the long run, it is still necessary to have their own core technologies, processes, and products.
After the volume is increased, the price will be adjusted.
Summarize the experience of special adjustment of the price of COVID-19 nucleic acid detection, scientifically grasp the price components of the inspection and testing project according to the principle of separating technical labor and material consumption, reduce the material consumption cost through centralized procurement and other ways, promote the reasonable decline of the total price of the project, and earnestly transmit the reform dividend to the masses.
Last year, the National Health Insurance Bureau issued a notice on the management of medical service prices, which in fact further clarified that under the premise of separating technology from consumption in the future, the pricing tone has been clarified. For those with high requirements for labor technology, the cost of labor should be higher, reflecting the value of medical personnel and improving performance. Price adjustments are inevitable for those who rely heavily on instrument automation.